InMed Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
IMLFF InMed Pharmaceuticals Inc
PNW Pinnacle West Capital Corp
AAPL Apple Inc
NAII Natural Alternatives International Inc
SJMiv.P Invesco BulletShares 2022 Hi Yld Corp Bd ETF
INTC Intel Corp
VAL Valaris PLC
GE General Electric Co
XOM Exxon Mobil Corp
MSFT Microsoft Corp

Health Care : Biotechnology | Small Cap Growth
Based in CanadaCompany profile

InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).

Closing Price
Day's Change
0.0234 (12.58%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

UnitedHealth's stock rallies to pace the Dow's gainers, after SunTrust boosts price target

9:59 am ET November 18, 2019 (MarketWatch)

Shares of UnitedHealth Group Inc. (UNH) rallied 2.2% in morning trading Monday, enough to pace the Dow Jones Industrial Average's gainers, after analyst David MacDonald at SunTrust Robinson Humphrey raised raised his price target to the highest on the Street. The managed care company's stock price gain was adding about 40 points to the Dow's price, while the Dow was down 11 points. MacDonald reiterated his buy rating on UnitedHealth's stock and raised his price target to $335 from $310, which makes him the most bullish of the 26 analysts surveyed by FactSet. "We have raised managed care price targets following the release of Senator Warren's plans to implement Medicare For All, which we think provide additional clarity and likely allays some concerns," MacDonald wrote in a note to clients. "We remain bullish on managed care and continue to view the companies as a key part of the healthcare cost solutions." Among price target increases, shares of WellCare Health Plans Inc. (WCG) rose 2.4%, Humana Inc. (HUM) tacked on 0.6%, Anthem Inc. (ANTM) hiked up 1.9%, Molina Healthcare Inc. (MOH) tacked on 3.1% and CVS Health Inc. (CVS) advanced 0.7% and Molina Healthcare Inc. (MOH) rallied 3.1%.

-Tomi Kilgore; 415-439-6400;

(END) Dow Jones Newswires

November 18, 2019 09:59 ET (14:59 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.